Clinical Trials
3 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05139095 2026-02-05
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting